CO.DON AG: Positive opinion from CHMP for EU approval of articular cartilage product
CO.DON AG (ISIN: DE DE000A1K0227)
Positive opinion from CHMP for EU approval of articular cartilage product
Berlin / Teltow, 18 May 2017 - In the course of the ongoing application for EU marketing authorisation CO.DON AG received today the official positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its articular cartilage product. The recommended indication is the repair of symptomatic articular cartilage defects on the femoral condyle and the knee patella; defects of up to 10 cm² for adults. The positive opinion by CHMP forms the basis for a decision by the European Commission on EU-wide marketing authorisation for the product. In the past, the European Commission followed the recommendations of the CHMP in the overwhelming number of applications.
Matthias Meißner, M.A.
18-May-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: CO.DON AG Warthestraße 21 14513 Teltow
Germany Phone: 03328 43460 Fax: 03328 434643 E-mail: firstname.lastname@example.org Internet: www.codon.de ISIN: DE000A1K0227 WKN: A1K022 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange End of Announcement DGAP News Service
575191 18-May-2017 CET/CEST